Publication

The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow

Pors, Klaus
; 
Goldberg, F.W.
; 
Leamon, C.P.
; 
Rigby, A.C.
; 
Snyder, S.A.
; 
Falconer, Robert A.
Publication Date
2009-11
End of Embargo
Supervisor
Keywords
Medicinal chemistry, Chemical biology, Diversity-oriented synthesis, EPSRC, Government funding, NCI, Cancer drug discovery
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Abstract
Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.
URI
http://hdl.handle.net/10454/8821
Version
No full-text in the repository
Citation
Pors K, Goldberg FW, Leamon CP et al (2009) The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discovery Today. 14 (21/22): 1045-50.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1016/j.drudis.2009.07.004
Type
Article
Qualification name
Notes